REPORT: Pushing the Limits of Bioanalysis - Overcoming Selectivity Challenges in Medical Device Studies

At Veloxity Labs, we're committed to pushing the boundaries of bioanalysis to ensure the success of our clients’ most challenging projects. In this report, we explore how our team overcame significant selectivity challenges during a medical device study that required precise validation in human plasma.

This report details our successful approach to optimizing a development method with an ultra-low limit of quantitation (LLOQ) of 30 pg/mL in human plasma—despite encountering unexpected interference during initial testing.

Through a series of innovative troubleshooting techniques, including the optimization of sample preparation, chromatography conditions and mobile phase modifications, we were able to overcome these challenges. Our efforts resulted in a streamlined, cost-effective solution that improved method efficiency, reduced analysis time by 70% and ensured the method's robustness for clinical development.

This report provides valuable insights into the complexities of bioanalysis and demonstrates Veloxity’s leadership in developing cutting-edge solutions that drive success in the pharmaceutical and biotechnology industries.

Download the Report